Literature DB >> 28746898

Circulating levels of the angiogenesis mediators endoglin, HB-EGF, BMP-9 and FGF-2 in patients with severe sepsis and septic shock.

Vanessa Boury Faiotto1, Daniel Franci1, Rodolfo Monteiro Enz Hubert1, Gleice Regina de Souza1, Maiara Marx Luz Fiusa1, Bidossessi Wilfried Hounkpe1, Thiago Martins Santos1, Marco Antonio Carvalho-Filho1, Erich Vinicius De Paula2.   

Abstract

PURPOSE: Endothelial barrier dysfunction is a hallmark of sepsis, and is at least partially mediated by pathways that regulate endothelial barrier assembly during angiogenesis. Not surprisingly, increased levels of key angiogenic proteins such as VEGF-A and Angiopoietin-2 have been described in sepsis. The purpose of this study was to investigate if additional pathways that regulate endothelial barrier integrity during angiogenesis could also be involved in the host response of sepsis.
MATERIAL AND METHODS: We evaluated circulating levels of four proteins involved in angiogenesis, not previously studied in sepsis, in a cohort of 50 patients with severe sepsis and septic shock.
RESULTS: Circulating levels of BMP-9 and FGF-2 were similar in patients and healthy volunteers. In contrast, patients with septic shock presented 1.5-fold higher levels of endoglin (P=0.004), and 2-fold lower levels of Heparin-Binding EGF-like growth factor (HB-EGF) (P=0.002) when compared to healthy individuals. Of note, HB-EGF deficiency has been recently demonstrated to be detrimental to survival in a murine model of sepsis.
CONCLUSIONS: Endoglin and HB-EGF could be involved in the host response of sepsis. Additional studies are warrant to investigate their role as biomarker or therapeutic targets in sepsis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; BMP-9; Endoglin; Endothelial barrier; FGF-2; HB-EGF; Sepsis

Mesh:

Substances:

Year:  2017        PMID: 28746898     DOI: 10.1016/j.jcrc.2017.07.034

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  6 in total

1.  Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome.

Authors:  Jane E Whitney; Rui Feng; Natalka Koterba; Fang Chen; Jenny Bush; Kathryn Graham; Simon F Lacey; Jan Joseph Melenhorst; Samir M Parikh; Scott L Weiss; Nadir Yehya
Journal:  Crit Care Explor       Date:  2020-12-04

2.  Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still's disease from sepsis.

Authors:  Tomohiro Koga; Remi Sumiyoshi; Kaori Furukawa; Shuntaro Sato; Kiyoshi Migita; Toshimasa Shimizu; Masataka Umeda; Yushiro Endo; Shoichi Fukui; Shin-Ya Kawashiri; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Fumiaki Nonaka; Akihiro Yachie; Hideaki Kondo; Takahiro Maeda; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2020-05-07       Impact factor: 5.156

Review 3.  Pathological angiogenesis and inflammation in tissues.

Authors:  Ji-Hak Jeong; Uttam Ojha; You Mie Lee
Journal:  Arch Pharm Res       Date:  2020-11-23       Impact factor: 4.946

Review 4.  Neutrophil Extracellular Traps, Angiogenesis and Cancer.

Authors:  Remo Poto; Leonardo Cristinziano; Luca Modestino; Amato de Paulis; Gianni Marone; Stefania Loffredo; Maria Rosaria Galdiero; Gilda Varricchi
Journal:  Biomedicines       Date:  2022-02-12

5.  Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19.

Authors:  Veronika Tomášková; Alexandra Mýtniková; Marcela Hortová Kohoutková; Ondřej Mrkva; Monika Skotáková; Michal Šitina; Kateřina Helánová; Jan Frič; Jiří Pařenica; Vladimír Šrámek; Martin Helán
Journal:  Front Med (Lausanne)       Date:  2022-08-31

6.  Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners.

Authors:  Eunate Gallardo-Vara; Lidia Ruiz-Llorente; Juan Casado-Vela; María J Ruiz-Rodríguez; Natalia López-Andrés; Asit K Pattnaik; Miguel Quintanilla; Carmelo Bernabeu
Journal:  Cells       Date:  2019-09-13       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.